Cargando…

Concerns about study design and suggestion of additional analysis of therapeutic drug monitoring-guided piperacillin/tazobactam therapy for patients with sepsis. Author’s reply

Detalles Bibliográficos
Autores principales:	Hagel, Stefan, Pletz, Mathias W., Lehmann, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205823/ https://www.ncbi.nlm.nih.gov/pubmed/35292826 http://dx.doi.org/10.1007/s00134-022-06669-2

Ejemplares similares

Another trial for the TARGET trial. Author’s reply
por: Hagel, Stefan, et al.
Publicado: (2022)

Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial
por: Hagel, Stefan, et al.
Publicado: (2022)

Therapeutic drug monitoring-based dose optimisation of piperacillin/tazobactam to improve outcome in patients with sepsis (TARGET): a prospective, multi-centre, randomised controlled trial
por: Hagel, Stefan, et al.
Publicado: (2019)

Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)

Correction to: Effect of therapeutic drug monitoring-based dose optimization of piperacillin/tazobactam on sepsis-related organ dysfunction in patients with sepsis: a randomized controlled trial
por: Hagel, Stefan, et al.
Publicado: (2022)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
por: Yang, Jihyun, et al.
Publicado: (2023)

Early Treatment Outcomes for Bloodstream Infections Caused by Potential AmpC Beta-Lactamase-Producing Enterobacterales with Focus on Piperacillin/Tazobactam: A Retrospective Cohort Study
por: Herrmann, Lena, et al.
Publicado: (2021)

Piperacillin/tazobactam Induced Myelosuppression
por: Lee, Kirsty Wai Chung, et al.
Publicado: (2009)

Early treatment response to piperacillin/tazobactam in patients with bloodstream infections caused by non-ESBL ampicillin/sulbactam-resistant Escherichia coli: a binational cohort study
por: Tobudic, Selma, et al.
Publicado: (2023)

DRESS syndrome induced by piperacillin-tazobactam
por: Sanchez-Gonzalez, Maria-Jose, et al.
Publicado: (2014)

Enterobacter endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
por: Singh, Trehan Hemant, et al.
Publicado: (2007)

Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis
por: Zaki, Syed Ahmed, et al.
Publicado: (2011)

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017)

Piperacillin/tazobactam: Eosinophilic-pneumonia: case report
Publicado: (2021)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock()
por: Sun, Yang, et al.
Publicado: (2023)

1555. Risk of Developing Acute Kidney Injury in Patients Receiving Piperacillin–Tazobactam and Vancomycin Compared with Those on Piperacillin–Tazobactam and Telavancin
por: Reilly, Joseph, et al.
Publicado: (2019)

Authors’ reply for “Considerations about causality in observational studies”
por: Wen, Bo, et al.
Publicado: (2021)

Pulmonary Penetration of Piperacillin and Tazobactam in Critically Ill Patients
por: Felton, T W, et al.
Publicado: (2014)

Tazobactam and piperacillin-induced thrombocytopenia: A case report
por: CHEN, HONG, et al.
Publicado: (2016)

Piperacillin/Tazobactam as Cause of Acute Generalized Exanthematous Pustulosis
por: Kyriakou, Aikaterini, et al.
Publicado: (2019)

Meropenem/piperacillin/tazobactam: Drug resistance: case report
Publicado: (2021)

Nephrotoxicity of concomitant piperacillin/tazobactam and teicoplanin compared with monotherapy
por: Workum, J D, et al.
Publicado: (2020)

Piperacillin/tazobactam/vancomycin: Cast nephropathy: case report
Publicado: (2022)

Piperacillin/tazobactam: Acute eosinophilic pneumonia: case report
Publicado: (2021)

Piperacillin-Tazobactam Allergies: An Exception to Usual Penicillin Allergy
por: Wong, Jane CY, et al.
Publicado: (2020)

612. Pharmacokinetics of Piperacillin-Tazobactam in Patients with Severe Infections
por: Rodríguez-Báez, Ana S, et al.
Publicado: (2022)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
por: Martin Mena, Anthony, et al.
Publicado: (2023)

Educating Health Professionals about Drug and Device Promotion: Authors' Reply
por: Mansfield, Peter R, et al.
Publicado: (2007)

Progression of kidney injury with the combination of vancomycin and piperacillin-tazobactam or cefepime in sepsis-associated acute kidney injury
por: Whitenack, Kaylee, et al.
Publicado: (2022)

Authors' Reply
por: Bush, Eliot C, et al.
Publicado: (2006)

Author's Reply
por: Kaeberlein, Matt, et al.
Publicado: (2006)

Authors' Reply
por: van Nimwegen, Erik, et al.
Publicado: (2006)

Authors' Reply
por: Nguyen, Hung D, et al.
Publicado: (2006)

Author’s reply
por: Manikandan, S
Publicado: (2011)

Author's Reply
por: Sharma, Sushil
Publicado: (2011)

Authors' reply
por: Khilnani, Gurudas
Publicado: (2008)

Authors’ reply
por: Singhal, Deepika, et al.
Publicado: (2012)

Authors’ reply
por: Melvin, George, et al.
Publicado: (2012)

Authors’ Reply
por: Reddy, Raghunatha R, et al.
Publicado: (2012)

Author's Reply
por: Zou, Zhitong
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_bdq6ink6mism0ntp61conkemqd